May 2008
Authors : CV Rizos1 , EN Liberopoulos1 , DP Mikhailidis2 , MS Elisaf3
Affliation :
1University of Ioannina, Department of Internal Medicine, School of Medicine, Ioannina, Greece
2University of London, Royal Free Hospital University College Medical School, Department of Clinical Biochemistry, London, UK
3Professor of Internal Medicine University of Ioannina, Department of Internal Medicine, School of Medicine, Ioannina, Greece ; ; , egepi@cc.uoi.gr
DOI : 10.1517/14656566.9.7.1087
Published in : Expert Opin. Pharmacother. Volume 9 Issue 7 2008 pages 1087 1108
Subject:
Keywords: atherogenesis , atherosclerosis , blood pressure , coagulation , creatinine , diabetes prevention , endothelial function , fat distribution , inflammation , lipids , liver function tests , peroxisome proliferator-activated receptors , pleiotropic effects , polycystic ovary syndrome , thiazolidinediones , uric acid
Please Login to read the full article.
- Actos suspension could shake up a market already in transition
- Immuron taking forward new therapy for fatty liver disease
- Takeda's diabetes pipeline moves forward as first-in-class GPR40 agonist enters Phase III
- Cancer a concern for BMS/AstraZeneca drug, but liver injury could be FDA panel focus
